Media
Press Releases
February 10, 2025
Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%
February 10, 2025
Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension
February 3, 2025
Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets
February 3, 2025
Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets
February 1, 2025
Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations
January 28, 2025
Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.06%
January 24, 2025
Lupin Receives U.S. FDA Approval for Sacubitril and Valsartan Tablets
January 24, 2025
Lupin Receives Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension
January 13, 2025
Lupin Launches Minzoya TM (Levonorgestrel and Ethinyl Estradiol Tablets, USP and Ferrous Bisglycinate Tablets) in the United States
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product